Daily Archives: January 29, 2020

Centrient Pharmaceuticals appoints Rex Clements as Chief Executive Officer after Karl Rotthier decides to step down from the role

Rex Clements

ROTTERDAM, The Netherlands, Jan. 29, 2020 (GLOBE NEWSWIRE) — Centrient Pharmaceuticals, the global leader in the production and commercialisation of sustainable antibiotics, next-generation statins and anti-fungals, is announcing that Karl Rotthier has decided to step down as CEO after having built a highly successful company over the last ten years and managing a smooth transition to the new ownership under Bain Capital.

Karl has successfully led the company for almost for 10 years, bringing Centrient to a unique position within the industry. Karl should be extremely proud for achieving these results. As Centrient is now well positioned on its growth trajectory for another potential record year in 2020, Karl decided that now is the best time to take a step back and let Centrient Pharmaceuticals be led by a new CEO who will bring fresh perspectives for the next phase of growth.

The Supervisory Board of Directors hereby announces the appointment of Rex Clements as new CEO, effective as of March 16, 2020. Rex Clements will have the mandate to drive and execute the strategy defined by the Supervisory Board of Directors and the Executive Committee, pursuing the growth trajectory the company has already set in motion.

Rex Clements is a recognised, well-rounded leader, with a proven track record in the pharmaceutical industry. He brings more than 20 years of rich experience gained across multiple assignments in the industry.

Karl Rotthier: It has been an extremely fulfilling experience to lead the Centrient Pharmaceuticals team to success over the last 10 years; culminating with Centrient becoming a true leader in our industry. Our Mission, Vision and Value Proposition make Centrient Pharmaceuticals unique in the market. I am proud and confident that the company is well positioned to keep growing over the coming years both organically and inorganically. The quality of our people and leadership will continue to make the difference in our highly competitive environment.

Ben Kunstler, Managing Director at Bain Capital Private Equity and Chairman of the Supervisory Board of Directors at Centrient Pharmaceuticals: “I want to thank Karl for his great leadership, professionalism and work ethic over the years. This was a decision Karl made over the last few months after careful consideration. The appointment of Rex Clements, a respected professional with substantial industry knowledge, as the CEO of Centrient Pharmaceuticals, will allow us to bring the company to an even greater level of performance through the focused pursuit of our growth ambitions. We are looking forward to actively work with Rex and set Centrient Pharmaceuticals on the path to long term, sustainable success.”

Rex Clements: “I am honored to join such a great company like Centrient Pharmaceuticals and to build on the success achieved by Karl. I look forward to working with the Centrient Supervisory Board of Directors, the Executive Committee and all of the employees of Centrient to keep raising the bar of the performance of the company and for our customers and patients.”

About Centrient Pharmaceuticals

Centrient Pharmaceuticals is the global leader in the production and commercialisation of sustainable antibiotics, next-generation statins and anti-fungals. We produce and sell intermediates, active pharmaceutical ingredients and finished dosage forms.

We stand proudly at the centre of modern healthcare, as a maker of essential and life-saving medicines. With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our over 2700 employees work continuously to meet our customers’ needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance.

Founded 150 years ago as the ‘Nederlandsche Gist- en Spiritusfabriek’, our company was known as Gist-Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rotterdam (Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, Egypt, the United States and Mexico. Centrient Pharmaceuticals is wholly owned by Bain Capital Private Equity, a leading global private investment firm.

For more information please visit www.centrient.com or contact Centrient Pharmaceuticals Corporate Communications, Alice Beijersbergen, Director Branding & Communications – E-Mail: alice.beijersbergen@centrient.com or Jean-Luc Giraud, Chief Human Resources & Communication Officer – E-mail: jean-luc.giraud@centrient.com.

Forward-looking statements
This press release may contain forward-looking statements with respect to Centrient Pharmaceuticals’ future financial performance and position. Such statements are based on current expectations, estimates and projections of Centrient and information currently available to the company. Centrient cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. Centrient has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is governing.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c976934a-938b-4f99-9830-a54488d60f47

Philips to repurchase up to 6 million shares to cover long-term incentive and employee stock purchase plans

January 29, 2020

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it will repurchase up to 6 million shares to cover certain of its obligations arising from its long-term incentive and employee stock purchase plans. At the current share price, the shares represent an amount of up to approximately EUR 260 million.

The repurchases will be executed through one or more individual forward transactions, to be entered into in the course of the first half of 2020, in accordance with the Market Abuse Regulation and within the limits of the authorization granted by the company’s General Meeting of Shareholders on May 9, 2019.  Further details will be available via this link. Philips will hold the repurchased shares in treasury until the shares are to be delivered.

Periodic update on transaction details related to Philips’ share repurchases
Philips is also conducting a EUR 1.5 billion repurchase program for capital reduction purposes, which was announced on January 29, 2019. Under this program, a total of 194,991 of its own common shares were repurchased in the period from January 24, 2020 up to and including January 27, 2020, with a weighted average purchase price of EUR 45.14. Further details can be found via this link.

For further information, please contact:

Ben Zwirs
Philips Global Press Office
Tel.: +31 6 15213446
E-mail: ben.zwirs@philips.com

Leandro Mazzoni
Philips Investor Relations
Tel.: +31 20 59 77222
E-mail: leandro.mazzoni@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips’ health technology portfolio generated 2019 sales of EUR 19.5 billion and employs approximately 80,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

Seatrade Cruise Global Announces Panelists, Themes for Anticipated 2020 State of the Global Cruise Industry Keynote

World’s Largest Cruise Industry Event Returns to Miami Beach Convention Center 20-23 April 2020

Lucy Hockings

Lucy Hockings, BBC World News broadcast journalist, is returning keynote panel moderator at Seatrade Cruise Global 2020.

NEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) — Seatrade Cruise Global, the cruise industry’s leading annual business-to-business event, announces its 2020 State of the Global Cruise Industry Keynote lineup – launching its 35th anniversary edition opening session on 21 April 2020 with dynamic dialogue and executive leaders from the largest and most luxurious cruise lines.

Sponsored by the Hong Kong Tourism Board and presented in partnership with Cruise Lines International Association (CLIA), the event kicks off with the State of the Global Cruise Industry panel, an exclusive round-table discussion joining senior leadership representing the world’s four largest cruise lines. The second panel, The Future of Luxury Cruising, will bring together five leaders in luxury liners to discuss the rapid growth and increasing demand for living the highlife on the high sea.

State of The Global Cruise Industry Panel

The State of the Global Cruise Industry Keynote brings senior leadership representing the world’s four largest cruise lines together.

“Our keynote opening session sets the tone for Seatrade Cruise Global 2020, welcoming attendees with a multifaceted dialogue reflective of our educational programming,” says Chiara Giorgi, Global Brand and Event Director for Seatrade Cruise. “As a marquee start of the conference, the State of the Global Cruise Industry panel will highlight the latest and greatest advancements and forward-thinking in the world of cruising.”

Lucy Hockings, BBC World News broadcast journalist, is the returning keynote panel moderator at Seatrade Cruise Global 2020.

“Cruising continues to gain popularity for leisure travelers, with more than 30 million guests expected to sail this year,” says Hockings. “Our discussions will take a deeper dive into how the industry is reimagining ships and partnering with destinations to embrace these changes and evolve the cruise experience for years ahead.”

KEYNOTE DISCUSSION | Overtourism Case Study: A Partnership Approach?

Mato Francović, Mayor of Dubrovnik, and Adam Goldstein, Vice Chairman, Royal Caribbean Cruises and CLIA Global Chair, join Seatrade Cruise News Editor Anne Kalosh to discuss how the city of Dubrovnik partnered with CLIA to tackle overtourism while establishing the city as a bellwether for destination-cruise line partnerships.

KEYNOTE PANEL | State of the Global Cruise Industry

Insights, expertise and perspectives on the future of cruising – touching on themes such as innovations on land and at sea, technology’s role in transforming customer experience, development on environmental improvements, collaborations for sustainable tourism and exciting new ship launches for 2020.

Panelists include:

  • Frank Del Rio, President & CEO, Norwegian Cruise Line Holdings
  • Arnold Donald, President & CEO, Carnival Corporation & PLC
  • Richard Fain, Chairman & CEO, Royal Caribbean Cruises Ltd.
  • Pierfrancesco Vago, Executive Chairman, MSC Cruises

KEYNOTE PANEL | The Future of Luxury Cruising
The demand for luxury cruising is on a rapid upward trajectory, with the market projected to more than double its capacity over the next decade. Cruise lines are making strides to offer unprecedented luxury at sea – from reaching uncharted destinations through adventurous expedition cruising to dishing out five-star dining experiences with onboard celebrity chefs. Leaders from today’s luxury liners will engage the audience in an insightful discussion exploring the new wave of advancements in this growing market and how to create distinct experiences that continue to charm discerning travelers.

2020 Registration Now Open
Seatrade Cruise Global offers flexible attendee registration options. Those who register by 21 February 2020, can take advantage of Early Bird pricing – savings as much as $400.

For pricing options and to register, CLICK HERE.

Press registration information can be found at seatradecruiseglobal.com/press-registration.

To learn more about Seatrade Cruise Global, visit seatradecruiseglobal.com. Follow Seatrade Cruise Global on social media: @SeatradeCruise on Twitter and @SeatradeCruiseEvents on Facebook and Instagram. #STCGlobal

About Seatrade Cruise Global
Seatrade Cruise Global 2020 is taking place 20-23 April 2020 at the Miami Beach Convention Center. The exhibition is the leading annual global B2B event for the cruise industry. Bringing together buyers and suppliers for a four-day conference and three-day exhibition, the gathering draws more than 13,000 registered attendees, over 700 exhibiting companies from 140 countries and more than 300 international journalists to become the cruise industry’s epicenter of ideas, products and services. Movers and shakers of the industry participate in a comprehensive panel of discussions featuring experts, leaders and thought-makers including the State of the Global Cruise Industry Keynote with the chief executives of the world’s largest cruise companies. Seatrade is organized by Informa Markets, a leading B2B information services group and the largest B2B Events organizer in the world. To learn more and for the latest news and information, visit www.informarkets.com.

FINN Partners
Virginia Sheridan / Luz Castillo

Photos accompanying this announcement are available at

Air Force’s three aircraft prepped to evacuate Indonesians from Wuhan

Jakarta (ANTARA) – The Indonesian Air Force has readied three aircraft for the evacuation of Indonesians from Wuhan, China, the epicenter of the coronavirus outbreak.

“We have readied two Boeing 737 and a C130 Hercules. The move is based on the result of our meeting two days ago with the Coordinating Ministry for Political, Legal, and Security Affairs; Health Ministry; and Foreign Affairs Ministry,” a spokesman of the Indonesian Air Force Air Commodore Fajar Adriyanto stated here on Wednesday.

The Air Force has also readied personnel from its health battalion, equipped with necessary medical equipment, he noted.

However, the Air Force awaits further instruction from the Foreign Affairs Ministry over the permit from the Government of China, as Wuhan has been on lockdown since January 23 to prevent further spread of the coronavirus.

“We are still waiting for the Foreign Affairs Ministry on whether they can obtain the permit from China. The Air Force is ready,” Adriyanto stated.

He could not as yet confirm the number of Indonesians to be evacuated from ground zero of the outbreak, though stating that each aircraft can take 100 to 200 Indonesians.

“We have also prepared equipment for the crews to prevent transmission of the virus. Their food must be monitored and would be under quarantine upon their arrival,” he stated.

The Foreign Affairs Ministry has recorded 243 Indonesians in China’s Hubei Province, of which 100 are in Wuhan City.

As of Wednesday morning, the death toll in the coronavirus outbreak has reached 132 in China, while 103 patients received hospital discharge.

According to the local authority, 5,997 people in China had contracted the 2019-nCov, including eight in Hong Kong, seven in Macau, and eight in Taiwan.

Some 9,239 other people were suspected of having been infected by the virus, and one new case was found in the Autonomous Region of Tibet in the southwest of China.

On Wednesday, hundreds of Japanese and Americans were airlifted out of Wuhan, with Australia to follow suit.

Source: ANTARA News

No Indonesian infected by nCov in Singapore: Embassy

All the patients are from Wuhan, China, and are now being treated at the National Centre for Infectious Diseases and Sengkang General Hospital of Singapore

Batam, Riau Islands (ANTARA) – The Indonesian Embassy in Singapore said that no Indonesian in the island republic was infected with the coronavirus (2019-nCov) until Tuesday (January 28).

There are seven confirmed cases of the coronavirus in Singapore but none of them has affected Indonesians, chief of the embassy’s information, social and cultural function, Ratna Lestari Harjana, said in an application message on Tuesday.

“All the patients are from Wuhan, China, and are now being treated at the National Centre for Infectious Diseases and Sengkang General Hospital of Singapore,” she said.

The embassy expressed hope that all Indonesians must stay alert over the virus and keep their bodies and environment clean, keep abreast of information from the Singapore Government and the Indonesian Embassy.

“The Indonesian Embassy in Singapore will keep monitoring and providing the latest information on handling cases of the said virus,” she said.

She said the Singapore Government has set up a Multi-Ministry Taskforce on the Wuhan Coronavirus aimed at coordinating with the Singapore Government’s responses in addressing the spread of the virus.

In addition, Singapore has also adopted principal steps, including issuing a call to its citizens not to unnecessarily travel to China.

It also heightened screening efforts on the air border using thermal scanners. To handle passengers of flights from China, an airport health team has been

Source: ANTARA News